Special issue: frontiers in recent advances on cancer diagnosis and treatment DOI Creative Commons
Bengt Westermark, Carl‐Henrik Heldin

Upsala Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 129, P. e11919 - e11919

Published: Dec. 31, 2024

‘Of all the processes that student of pathology is privileged to study, none as intriguing, fascinating, and perplexing neoplasia.’ This statement, a quote from William Boyd’s Textbook Pathology (1961), remains thought-provoking today when it was first written. Over decades since Boyd penned these words, our understanding molecular mechanisms underlying tumorigenesis development novel therapeutic approaches have advanced at revolutionary pace. special issue UJMS on cancer exemplifies remarkable progress in research, reaffirming perspective enigmatic nature endures.

Language: Английский

Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity DOI Creative Commons
Chuannan Fan, Qian Wang, Peter H.L. Krijger

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 25, 2025

Enhancer RNAs (eRNAs) are a pivotal class of enhancer-derived non-coding that drive gene expression. Here we identify the SNAI1 enhancer RNA (SNAI1e; SCREEM2) as key activator expression and potent enforcer transforming growth factor-β (TGF-β)/SMAD signaling in cancer cells. SNAI1e depletion impairs TGF-β-induced epithelial-mesenchymal transition (EMT), migration, vivo extravasation, stemness, chemotherapy resistance breast functions an eRNA to cis-regulate activity by binding strengthening enrichment transcriptional co-activator bromodomain containing protein 4 (BRD4) at local enhancer. selectively promotes SNAI1, which encodes EMT transcription factor SNAI1. Furthermore, reveal interacts with anchors inhibitory SMAD7 nucleus, thereby prevents TGF-β type I receptor (TβRI) polyubiquitination proteasomal degradation. Our findings establish critical driver cell plasticity. regulate cancer. Here, authors expression, promoting EMT, enhancing BRD4

Language: Английский

Citations

0
A pyroptosis-related lncRNA risk model for the prediction of prognosis and immunotherapy response in head and neck squamous cell carcinoma DOI Creative Commons
Jingyuan Ren,

Bingrui Yan,

Xurui Wang

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 12, 2024

Background Recent research has highlighted pyroptosis as a key factor in cancer progression. This study aims to explore the association between pyroptosis-related signatures and overall survival (OS) head neck squamous cell carcinoma (HNSC) develop long non-coding RNA (lncRNA) risk model predict prognosis response immunotherapy HNSC. Methods We extracted expression data for 18 genes identified lncRNA probes specific HNSC by using datasets from Gene Expression Omnibus (GEO) The Cancer Genome Atlas (TCGA). Consensus clustering was performed categorize patients into distinct subtypes. A six-lncRNA score constructed through univariate least absolute shrinkage selection operator (LASSO) Cox regression analyses. evaluated predictive ability of patients’ response. immunohistochemistry (IHC) Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR). Results Our analysis revealed two subtypes patients, Cluster B. Notably, B exhibited significantly poorer compared those A. Through differential analysis, we six lncRNAs (AC002331.1, CTA-384D8.35, RP11-291B21.2, AC006262.5, RP1-27K12.2, RP11-54H7.4) that were differentially expressed these clusters. 6-lncRNA developed, which successfully stratified high- low-risk groups with outcomes. Validation RT-qPCR confirmed tumor tissues adjacent normal tissues, found CTA-384D8.35 increased group (t=-6.203, P<0.001). Furthermore, demonstrated significant patient immunotherapy, exhibiting higher objective rate immune checkpoint blockade (ICB) therapy longer high-risk group. Conclusion underscores role identifies differing offers valuable tool predicting potential benefits ICB therapy. These findings highlight importance associated microenvironment, paving way novel targeted therapies

Language: Английский

Citations

1
Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors DOI Creative Commons
Kangning Zhao, Jinlong Zhang, Lin Zhou

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 25, 2024

Scutellaria baicalensis has been used for the treatment of digestive system disorders thousands years in China and other regions. Modern research have revealed its therapeutic efforts tumors. Thus, to review updated progress S. main flavonoids tumors past 10 years, this article summarized effect molecular mechanisms 5 on oral cavity, esophagus, stomach, colon, liver, pancreas by inhibiting tumor cell proliferation, inducing autophagy, stimulating immune response, increasing drug sensitivity. In conclusion, could be applied treat with different type methods.

Language: Английский

Citations

0
Special issue: frontiers in recent advances on cancer diagnosis and treatment DOI Creative Commons
Bengt Westermark, Carl‐Henrik Heldin

Upsala Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 129, P. e11919 - e11919

Published: Dec. 31, 2024

‘Of all the processes that student of pathology is privileged to study, none as intriguing, fascinating, and perplexing neoplasia.’ This statement, a quote from William Boyd’s Textbook Pathology (1961), remains thought-provoking today when it was first written. Over decades since Boyd penned these words, our understanding molecular mechanisms underlying tumorigenesis development novel therapeutic approaches have advanced at revolutionary pace. special issue UJMS on cancer exemplifies remarkable progress in research, reaffirming perspective enigmatic nature endures.

Language: Английский

Citations

0